Author

Emily Wearne

Institutions: University of Minnesota, United States Food and Drug Administration, Johns Hopkins University, University of Alabama, University of Virginia

Observed institutions: University of Minnesota, United States Food and Drug Administration, Center for Drug Evaluation and Research, Johns Hopkins University, University of Alabama, University of Virginia

ORCID: 0000-0001-8912-2378

Observed ORCID: 0000-0001-8912-2378

OpenAlex ID: A5030061648

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

2021 · Erica C. Nakajima, Nicole Drezner, et al. · Clinical Cancer Research · 328

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

2021 · Janice Kim, Diana Bradford, et al. · Clinical Cancer Research · 109

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

2023 · Katie Chon, Erin Larkins, et al. · Clinical Cancer Research · 61

FDA Approval Summary: TAS-102

2017 · Leigh Marcus, Steven J. Lemery, et al. · Clinical Cancer Research · 53

An FDA oncology analysis of immune activating products and first-in-human dose selection

2016 · Haleh Saber, Ramadevi Gudi, et al. · Regulatory Toxicology and Pharmacology · 53

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

2022 · Elizabeth S. Duke, Amy K. Barone, et al. · Clinical Cancer Research · 52

FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

2022 · Elizabeth S. Duke, Liza Stapleford, et al. · Clinical Cancer Research · 48

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

2024 · Elizabeth S. Duke, Diana Bradford, et al. · Journal of Clinical Oncology · 21

Clinical Development of Pediatric Program within Rare Diseases

2023 · Jingjing Ye, Lian Ma, et al. · Chapman & Hall/CRC eBooks · 4

Evaluating “brain permeability”: A critical issue for the development of therapeutic agents for primary and metastatic brain tumors

2026 · Stuart A Grossman, Amy Barone, et al. · Neuro-Oncology · 3

Supplementary Table S1: Exploratory analysis of ORR by clinical and demographic subgroups from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

2025 · Katie Chon, Erin Larkins, et al.

Data from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

2025 · Katie Chon, Erin Larkins, et al.

Supplementary Tables S1-S3 from FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

2023 · Janice Kim, Diana Bradford, et al.

Supplementary Tables S1-S3 from FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

2023 · Janice Kim, Diana Bradford, et al.

Data from FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

2023 · Janice Kim, Diana Bradford, et al.

Data from FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

2023 · Janice Kim, Diana Bradford, et al.

Works count: 16

Citation count: 731

H-index: 8

I10-index: 8